Tissue Sensor to Reduce the Need for Controlled Apnea During Retrograde Intrarenal Surgery (Tissue Sensor)

September 30, 2026 updated by: Malkhasyan Vigen Andreevich, Botkin Hospital

Retrograde intrarenal surgery is an established minimally invasive treatment for renal stones. During laser lithotripsy, respiratory motion causes the kidney, renal collecting system, and stone to move relative to the distal tip of the laser fiber. This can impair precise fiber positioning, reduce operative-field stability, and increase the risk of unintended laser exposure of the urothelium of the renal collecting system.

To reduce respiratory motion of the kidney, the surgeon may ask the anesthesiologist to temporarily pause mechanical ventilation. Controlled apnea can briefly stabilize the operative field; however, it requires interruption of ventilation and may cause oxygen desaturation, carbon dioxide accumulation, hemodynamic changes, and increased anesthetic burden.

Tissue Sensor is a technology that automatically terminates laser emission when contact between the distal tip of the laser fiber and tissue is detected. Tissue Sensor is expected to reduce the risk of unintended laser exposure of the renal collecting-system mucosa during respiratory motion of the kidney.

Greater surgeon confidence in the safety of laser activation may reduce the need to stabilize the kidney with controlled apnea. At the same time, brief automatic interruptions of laser emission may increase lithotripsy time and total operative time.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or older.
  • A single renal stone.
  • An indication for elective RIRS.
  • Feasibility of performing the intervention with a flexible ureteroscope.
  • Recommended stone diameter on CT: 7-15 mm.
  • Stone located in a calyx, a group of calyces, or the renal pelvis.
  • Feasibility of TFL use.
  • General anesthesia with controlled mechanical ventilation.
  • No active urinary tract infection.
  • Ability to undergo low-dose non-contrast CT at 1 month.
  • Signed written informed consent.

Exclusion Criteria:

  • Multiple stones in the study kidney.
  • Complete or partial staghorn stone.
  • Ipsilateral ureteral stone.
  • Renal or upper urinary tract anomaly that substantially alters the anatomy.
  • Horseshoe, pelvic, or ectopic kidney.
  • Stone within a calyceal diverticulum.
  • Ureteral stricture.
  • Previous reconstructive surgery involving the study kidney or ureter.
  • Active infection, obstructive pyelonephritis, or urosepsis.
  • Nephrostomy drainage.
  • Pregnancy.
  • Severe respiratory failure or a contraindication to apnea.
  • Severe cardiovascular instability.
  • Inability to undergo general anesthesia.
  • Combined, bilateral, or percutaneous intervention.
  • Suspected upper urinary tract tumor.
  • Inability to comply with the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patients with a single renal stone who are scheduled for elective retrograde intrarenal surger

RIRS will be performed using a thulium fiber laser with Tissue Sensor activated. All automatic system trigger events will be recorded and, whenever possible, synchronized with the procedure video recording.

RIRS will be performed using the same TFL system with Tissue Sensor deactivated. Visually confirmed contacts between the activated laser fiber and the mucosa will be recorded from the procedure video.

RIRS will be performed using a thulium fiber laser with Tissue Sensor activated. All automatic system trigger events will be recorded and, whenever possible, synchronized with the procedure video recording.

  • total number of Tissue Sensor trigger events;
  • Tissue Sensor trigger events per minute of laser activation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of patients requiring at least one episode of controlled intraoperative apnea during laser lithotripsy.
Time Frame: intraoperative
intraoperative

Secondary Outcome Measures

Outcome Measure
Time Frame
• number of apnea episodes;
Time Frame: intraoperative
intraoperative
total apnea duration;
Time Frame: intraoperative
intraoperative
mean number of apnea episodes per patient;
Time Frame: intraoperative
intraoperative
maximum duration of a single apnea episode;
Time Frame: intraoperative
intraoperative
minimum SpO2;
Time Frame: intraoperative
intraoperative
incidence of desaturation;
Time Frame: intraoperative
intraoperative
visible laser-induced mucosal
Time Frame: intraoperative
intraoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

November 2, 2028

Study Registration Dates

First Submitted

September 17, 2026

First Submitted That Met QC Criteria

September 30, 2026

First Posted (Actual)

October 1, 2026

Study Record Updates

Last Update Posted (Actual)

October 1, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • MoscowBotkinHospital3

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe